Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy

On June 10, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab (OPDIVO; Bristol Myers Squibb, New York, NY) for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine‐ and platinum‐based...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Pelosof, Lorraine, Saung, May Tun, Donoghue, Martha, Casak, Sandra, Mushti, Sirisha, Cheng, Joyce, Jiang, Xiling, Liu, Jiang, Zhao, Hong, Khazraee, Maryam, Goldberg, Kirsten B., Theoret, Marc, Lemery, Steven, Pazdur, Richard, Fashoyin‐Aje, Lola
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2021
Schlagworte:
Regulatory Issues: FDA
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018317/
https://ncbi.nlm.nih.gov/pubmed/33345396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13646
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge